SG11201706211PA - Non-natural semaphorins 3 and their medical use - Google Patents
Non-natural semaphorins 3 and their medical useInfo
- Publication number
- SG11201706211PA SG11201706211PA SG11201706211PA SG11201706211PA SG11201706211PA SG 11201706211P A SG11201706211P A SG 11201706211PA SG 11201706211P A SG11201706211P A SG 11201706211PA SG 11201706211P A SG11201706211P A SG 11201706211PA SG 11201706211P A SG11201706211P A SG 11201706211PA
- Authority
- SG
- Singapore
- Prior art keywords
- semaphorins
- natural
- medical use
- medical
- natural semaphorins
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Communicable Diseases (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Hematology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15156195 | 2015-02-23 | ||
PCT/EP2016/053750 WO2016135130A1 (en) | 2015-02-23 | 2016-02-23 | Non-natural semaphorins 3 and their medical use |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201706211PA true SG11201706211PA (en) | 2017-09-28 |
Family
ID=52596769
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201706211PA SG11201706211PA (en) | 2015-02-23 | 2016-02-23 | Non-natural semaphorins 3 and their medical use |
Country Status (12)
Country | Link |
---|---|
US (1) | US10906948B2 (en) |
EP (1) | EP3262064A1 (en) |
JP (1) | JP6959869B2 (en) |
KR (1) | KR20170138410A (en) |
CN (1) | CN107810192A (en) |
AU (1) | AU2016223584B2 (en) |
BR (1) | BR112017017825A2 (en) |
CA (1) | CA2976593A1 (en) |
IL (1) | IL253872B (en) |
RU (1) | RU2722832C2 (en) |
SG (1) | SG11201706211PA (en) |
WO (1) | WO2016135130A1 (en) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2016287787B2 (en) | 2015-06-29 | 2021-10-28 | The University Of British Columbia | B1SP fusion protein therapeutics, methods, and uses |
JP6820014B2 (en) * | 2015-07-09 | 2021-01-27 | 学校法人順天堂 | Evaluation method of lymph node metastasis ability of endometrial cancer |
WO2019207051A1 (en) | 2018-04-25 | 2019-10-31 | Università Degli Studi Di Torino | Medical use of combinations of non-natural semaphorins 3 and antimetabolites |
CN109821009B (en) * | 2019-01-22 | 2020-03-31 | 南京医科大学 | Medical application of axon guidance factor recombinant protein Semaphorin3G |
CN112641928A (en) * | 2019-10-11 | 2021-04-13 | 田中纯美 | Polypeptide for angiogenesis and lymphangiogenesis related diseases and application thereof |
CN110684805B (en) * | 2019-11-19 | 2023-08-01 | 四川大学华西医院 | Application of nerve guidance factor Sema gene recombination slow virus vector in preparation of medicine for treating osteoarthritis |
CN111009287B (en) * | 2019-12-20 | 2023-12-15 | 东软集团股份有限公司 | SLiMs prediction model generation method, device, equipment and storage medium |
WO2021245670A1 (en) * | 2020-06-04 | 2021-12-09 | Medical Research & Development Fund for Health Services Bnai Zion Medical Center | Modified semaphorin 3a, compositions comprising the same and uses thereof |
CN112687338B (en) * | 2020-12-31 | 2022-01-11 | 云舟生物科技(广州)有限公司 | Method for storing and restoring gene sequence, computer storage medium and electronic device |
CN114288292B (en) * | 2021-12-10 | 2023-06-13 | 中南大学湘雅医院 | Application of aromatic compound as activator of nerve Cong Su protein-B2 in preparation of medicine for treating osteoporosis |
WO2023114245A2 (en) * | 2021-12-14 | 2023-06-22 | Radin Daniel Pierce | Compositions and methods for treating cancers of the central nervous system (cns), including glioblastoma and chemoresistant cns tumors, and related compositions and methods for inhibiting and eliminating cns cancer stem cells |
CN115947817A (en) * | 2023-02-22 | 2023-04-11 | 广州庆毅生物医药科技有限公司 | Tumor-related polypeptide and preparation method and application thereof |
CN116790610A (en) * | 2023-05-18 | 2023-09-22 | 四川大学 | Gene for treating bone diseases and gene therapeutic drug using AAV as vector |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
DE3169595D1 (en) | 1980-11-10 | 1985-05-02 | Gersonde Klaus | Method of preparing lipid vesicles by ultrasonic treatment, the use of this method and apparatus for its application |
IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
DE3374837D1 (en) | 1982-02-17 | 1988-01-21 | Ciba Geigy Ag | Lipids in the aqueous phase |
DE3218121A1 (en) | 1982-05-14 | 1983-11-17 | Leskovar, Peter, Dr.-Ing., 8000 München | Pharmaceutical compositions for tumour treatment |
EP0102324A3 (en) | 1982-07-29 | 1984-11-07 | Ciba-Geigy Ag | Lipids and surfactants in an aqueous medium |
US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
JPS607934A (en) | 1983-06-29 | 1985-01-16 | Dai Ichi Seiyaku Co Ltd | Preparation of liposome |
HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
EP0142641B1 (en) | 1983-09-26 | 1991-01-16 | Udo Dr. Ehrenfeld | Means and product for the diagnosis and therapy of tumours and for the treatment of weaknesses of the cellular and humoral immune system |
EP0143949B1 (en) | 1983-11-01 | 1988-10-12 | TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION | Pharmaceutical composition containing urokinase |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US20040049014A1 (en) | 1988-12-28 | 2004-03-11 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
DK0590058T3 (en) | 1991-06-14 | 2004-03-29 | Genentech Inc | Humanized heregulin antibody |
GB9304200D0 (en) | 1993-03-02 | 1993-04-21 | Sandoz Ltd | Improvements in or relating to organic compounds |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
EP0625200B1 (en) | 1992-02-06 | 2005-05-11 | Chiron Corporation | Biosynthetic binding protein for cancer marker |
WO1994029469A2 (en) | 1993-06-07 | 1994-12-22 | Vical Incorporated | Plasmids suitable for gene therapy |
US5639856A (en) * | 1993-09-13 | 1997-06-17 | The Regents Of The University Of California | Semaphorin gene family |
US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
EP0833907A1 (en) | 1995-06-23 | 1998-04-08 | President And Fellows Of Harvard College | Transcriptional regulation of genes encoding vascular endothelial growth factor receptors |
KR100508289B1 (en) | 1998-04-21 | 2005-08-17 | 마이크로메트 에이지 | Cd19×cd3 specific polypeptides and uses thereof |
WO2001023425A1 (en) | 1999-09-28 | 2001-04-05 | Universität Zürich | Factors having prion-binding activity in serum and plasma and agents to detect transmissible spongiform encephalopathitis |
CN101289511A (en) | 2000-04-11 | 2008-10-22 | 杰南技术公司 | Multivalent antibodies and uses therefore |
AU8470301A (en) | 2000-08-03 | 2002-02-18 | Wim-Van Schooten | Production of humanized antibodies in transgenic animals |
US7290975B2 (en) | 2001-03-17 | 2007-11-06 | Mechanical Tech & Engineering Co. | Two-speed passenger lift and pump assembly therefor |
US7781413B2 (en) * | 2001-10-31 | 2010-08-24 | Board Of Regents, The University Of Texas System | SEMA3B inhibits tumor growth and induces apoptosis in cancer cells |
US7184284B2 (en) | 2004-03-30 | 2007-02-27 | Micron Technology, Inc. | Closed-loop high voltage booster |
JP5102772B2 (en) | 2005-11-29 | 2012-12-19 | ザ・ユニバーシティ・オブ・シドニー | Demibody: Dimerization activation therapeutic agent |
US9107884B2 (en) * | 2007-02-02 | 2015-08-18 | Biogen Ma Inc. | Use of semaphorin 6A for promoting myelination and oligodendrocyte differentiation |
EP2210092B1 (en) | 2007-10-19 | 2014-06-11 | Rappaport Family Institute for Research in the Medical Sciences | Compositions comprising semaphorins for the treatment of angiogenesis related diseases and methods of selection thereof |
WO2011066284A1 (en) * | 2009-11-25 | 2011-06-03 | The University Of North Carolina At Chapel Hill | Methods and compositions for the treatment of immune disorders |
EP3677310A1 (en) * | 2012-10-08 | 2020-07-08 | St. Jude Children's Research Hospital | Therapies based on control of regulatory t cell stability and function via a neuropilin-1:semaphorin axis |
-
2016
- 2016-02-23 CA CA2976593A patent/CA2976593A1/en active Pending
- 2016-02-23 WO PCT/EP2016/053750 patent/WO2016135130A1/en active Application Filing
- 2016-02-23 CN CN201680011456.5A patent/CN107810192A/en active Pending
- 2016-02-23 US US15/552,511 patent/US10906948B2/en active Active
- 2016-02-23 JP JP2017562129A patent/JP6959869B2/en active Active
- 2016-02-23 AU AU2016223584A patent/AU2016223584B2/en active Active
- 2016-02-23 KR KR1020177026803A patent/KR20170138410A/en not_active Application Discontinuation
- 2016-02-23 BR BR112017017825-7A patent/BR112017017825A2/en not_active IP Right Cessation
- 2016-02-23 EP EP16709710.4A patent/EP3262064A1/en active Pending
- 2016-02-23 SG SG11201706211PA patent/SG11201706211PA/en unknown
- 2016-02-23 RU RU2017128465A patent/RU2722832C2/en active
-
2017
- 2017-08-07 IL IL253872A patent/IL253872B/en active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
AU2016223584A1 (en) | 2017-08-17 |
RU2017128465A (en) | 2019-03-25 |
EP3262064A1 (en) | 2018-01-03 |
JP2018506994A (en) | 2018-03-15 |
WO2016135130A1 (en) | 2016-09-01 |
AU2016223584B2 (en) | 2020-11-19 |
BR112017017825A2 (en) | 2018-04-10 |
US10906948B2 (en) | 2021-02-02 |
RU2722832C2 (en) | 2020-06-04 |
JP6959869B2 (en) | 2021-11-05 |
IL253872B (en) | 2021-04-29 |
CA2976593A1 (en) | 2016-09-01 |
CN107810192A (en) | 2018-03-16 |
US20180030100A1 (en) | 2018-02-01 |
RU2017128465A3 (en) | 2019-07-24 |
KR20170138410A (en) | 2017-12-15 |
IL253872A0 (en) | 2017-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL253872A0 (en) | Non-natural semaphorins 3 and their medical use | |
HK1247614A1 (en) | Therapeutic compounds and uses thereof | |
HK1248697A1 (en) | Therapeutic compounds and uses thereof | |
SG10202010420TA (en) | Patient interface and aspects thereof | |
IL283335B (en) | Dihydropyrimidin-2-one compounds and medical use thereof | |
ZA201802256B (en) | Compounds and therapeutic uses thereof | |
GB201617064D0 (en) | Compounds and their therapeutic use | |
GB201715194D0 (en) | Compounds and their therapeutic use | |
HK1253725A1 (en) | Novel antimicrobial peptide and use thereof | |
ZA201801134B (en) | Hydroxytriazine compound and medical use thereof | |
GB201511207D0 (en) | Isolated organ evaluation and treatment | |
GB201709840D0 (en) | Methods and medical uses | |
SG11201710686PA (en) | Hair treatment agent | |
GB201503139D0 (en) | Diagnostic and therapeutic target | |
GB201700526D0 (en) | Therapeutic use | |
PL3341481T3 (en) | Microrna-328 anti-sense composition and therapeutic use | |
PL3129398T3 (en) | New medical agents and uses thereof | |
GB201420805D0 (en) | Ligatures and use thereof | |
GB201713975D0 (en) | Medical use | |
GB201709837D0 (en) | Methods and medical uses | |
GB201703768D0 (en) | Skin treatment methods | |
GB201703734D0 (en) | Skin treatment methods | |
GB201509693D0 (en) | Orthopaedic and dental material | |
GB201504865D0 (en) | Therapeutic and diagnostic target | |
GB201504863D0 (en) | Therapeutic and diagnostic target |